Scientists from the University of Miami Miller School of Medicine may have uncovered a new strategy to weaken pancreatic cancer’s defenses, potentially improving the effectiveness of current treatments. In a recent study, researchers discovered that blocking a protein called IL1RAP — which plays a key role in the body’s inflammatory responses — could disrupt a complex network that helps pancreatic cancer cells survive and resist treatment. In laboratory experiments, this approach reduced the number of tumor-supporting cells and fibrosis, while increasing the activity of T cells, which are crucial for fighting cancer. The next step is a planned clinical trial that will test a combination of IL1RAP-targeted therapy with chemoimmunotherapy in patients with operable pancreatic cancer before surgery. This would be the first neoadjuvant clinical trial of its kind, aiming to assess whether this new approach can make existing treatments more effective. The research, published in JCI Insight, was led by Dr. Jashodeep Datta and his team, who explained how IL1RAP connects tumor cells, immune cells, and fibroblasts into a coordinated system that helps cancer resist treatment. Pancreatic cancer is particularly challenging because its tumors often create an environment that is both highly inflamed and suppresses the immune system. This "inflamed but immune-suppressed" state makes it difficult for chemotherapy and immunotherapy to work well. IL1RAP appears to play a central role in maintaining this environment. When the protein is blocked, it disrupts a shared receptor that many inflammatory signals rely on, potentially interfering with a broader network that supports the tumor. In preclinical studies, blocking IL1RAP led to significant changes in the tumor’s environment. Immune-suppressive cells decreased, while T cells became more active and effective. The tumors also showed reduced fibrosis and a stronger response to combination treatment. This research is supported by a Translational Research Grant from the V Foundation, which funds promising studies that aim to move new treatments from the lab to clinical trials. The grant, awarded to Datta and his team, provides $800,000 over four years to support this "bench-to-bedside" research.